Breaking News

Catalent Expands Biologics Capabilities in UK and Europe

Acquires facility in Oxfordshire and will invest up to $160 million to complete and equip it with state-of-the-art capabilities for biologics and vaccines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent has acquired a biologics development and manufacturing facility currently under construction near Oxford, U.K., from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.)   Catalent plans to invest up to $160 million to complete the building of the facility and equip it with state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins, and other advanced modalities. It is expected that the new facilit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters